AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 111 filers reported holding AKERO THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 8.03 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $119,792,559 | +8.3% | 2,368,378 | 0.0% | 0.69% | +7.8% |
| Q2 2023 | $110,579,569 | +22.0% | 2,368,378 | 0.0% | 0.64% | +29.8% |
| Q1 2023 | $90,614,142 | -30.2% | 2,368,378 | 0.0% | 0.49% | -36.7% |
| Q4 2022 | $129,787,114 | +60.9% | 2,368,378 | 0.0% | 0.78% | +47.5% |
| Q3 2022 | $80,643,000 | +7106.7% | 2,368,378 | +1900.7% | 0.53% | +8700.0% |
| Q2 2022 | $1,119,000 | -33.4% | 118,378 | 0.0% | 0.01% | -40.0% |
| Q1 2022 | $1,680,000 | -32.9% | 118,378 | 0.0% | 0.01% | -16.7% |
| Q4 2021 | $2,504,000 | -5.4% | 118,378 | 0.0% | 0.01% | 0.0% |
| Q3 2021 | $2,646,000 | -9.9% | 118,378 | 0.0% | 0.01% | -7.7% |
| Q2 2021 | $2,937,000 | -14.5% | 118,378 | 0.0% | 0.01% | -13.3% |
| Q1 2021 | $3,434,000 | +12.4% | 118,378 | 0.0% | 0.02% | +25.0% |
| Q4 2020 | $3,054,000 | -24.7% | 118,378 | -10.2% | 0.01% | -25.0% |
| Q3 2020 | $4,058,000 | – | 131,788 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 5,830,203 | $179,512,000 | 24.20% |
| venBio Partners LLC | 2,444,311 | $75,260,000 | 11.44% |
| Versant Venture Management, LLC | 777,727 | $23,946,000 | 4.38% |
| Redmile Group, LLC | 2,336,357 | $71,936,000 | 1.32% |
| Vivo Capital, LLC | 571,833 | $17,607,000 | 1.02% |
| Cormorant Asset Management, LP | 859,550 | $26,466,000 | 1.02% |
| Boxer Capital, LLC | 831,495 | $25,602,000 | 0.88% |
| Integral Health Asset Management, LLC | 85,000 | $2,617,000 | 0.80% |
| EAM Global Investors LLC | 49,718 | $1,531,000 | 0.56% |
| Crawford Lake Capital Management, LLC | 43,826 | $1,349,000 | 0.56% |